Canadian wildfire smoke could affect several sensitive groups, AHN pulmonologist says
The haze Pittsburgh-area residents will see in the sky on Tuesday is coming from wildfires in Canada.
Blown by the current prevailing winds, that smoke is a point of concern, especially for the vulnerable.
While the smoke may have come a long way, somewhere in the neighborhood of 1,300 miles, the distance hasn't diminished the threat.
"You know the people with bad COPD or asthma, or people who have underlying lung disease for other reasons, those are the folks I really worry about," said Allegheny Health Network pulmonologist Dr. Tariq Cheema.
What about the general population?
"Children and older adults. That's the population."
Dr. Cheema says that what you see is what you breathe.
"Especially with these particles and smoke, you know, they can sometimes embed in your lungs, and then it irritates the lungs, and then you start coughing. You start coughing up all that stuff," Dr. Cheema said.
Even if you don't have chronic lung issues, we're all breathing the same haze or smoke.
"You'll just kind of feel like the air is heavy. Some people may have an irritant, they'll start coughing, a dry cough, just like you would be exposed to, like at a barbecue, or you're exposed to somebody else smoking around you," Dr. Cheema said.
The coming rain could bring relief.
What can you do if you're in one of these vulnerable groups?
"Stay indoors, if you can. Keep the air conditioning on, keep the windows closed. If you do have to go outside, wear a mask, an N95 if you have one. If not, even a regular mask will do."
While the amount of smoke right now is fairly light, it's building and settling in. The rain can't come soon enough.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
28 minutes ago
- Forbes
FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes
AI at the FDA getty The U.S. Food and Drug Administration announced this week that it deployed a generative AI tool called ELSA (Evidence-based Learning System Assistant), across its organization. After a low-profile pilot that delivered measurable gains, the system is now in use by staff across the agency, several weeks ahead of its original schedule. Dr. Marty Makary, the FDA's commissioner, shared a major outcome. A review task that once took two or three days now takes six minutes. 'Today, we met our goal ahead of schedule and under budget,' said Makary. 'What took one scientific reviewer two to three days [before] The FDA has thousands of reviewers, analysts, and inspectors who deal with massive volumes of unstructured data such as clinical trial documents, safety reports, inspection records. Automating any meaningful portion of that stack creates outsized returns. ELSA helps FDA teams speed up several essential tasks. Staff are already using it to summarize adverse event data for safety assessments, compare drug labels, generate basic code for nonclinical database setup, and identify priority sites for inspections, among other tasks. This last item, using data to rank where inspectors should go, could have a real-world impact on how the FDA oversees the drug and food supply chain and impacts on how the FDA delivers its services. Importantly, however, the tool isn't making autonomous decisions without a human in the loop. The system prepares information so that experts can decide faster. It cuts through the routine, not the judgment. One of the biggest questions about AI systems in the public sector revolves around the use of data and third party AI systems. Makary addressed this directly by saying that 'All information stays within the agency. The AI models are not being trained on data submitted by the industry.' That's a sharp contrast to the AI approaches being taken in the private sector, where many large language models have faced criticism over training on proprietary or user-submitted content. In the enterprise world, this has created mounting demand for "air-gapped" AI solutions that keep data locked inside the company. That makes the FDA's model different from many corporate tools, which often rely on open or external data sources. The agency isn't building a public-facing product. It's building a controlled internal system, one that helps it do its job better. Federal departments have been slow to move past AI experimentation. The Department of Veterans Affairs has started testing predictive tools to manage appointments. The SEC has explored market surveillance AI for years. But few have pushed into full and widespread production. The federal government has thousands of employees processing huge volumes of information, most of it unstructured sitting in documents, files, and even paper. That means AI is being focused most on operational and process-oriented activities. It's shaping up to be a key piece of how agencies process data, make recommendations, and act. Makary put it simply that ELSA is just the beginning for AI adoption within the FDA. 'Today's rollout of ELSA will be the first of many initiatives to come,' he said. 'This is how we'll better serve the American people.'
Medscape
38 minutes ago
- Medscape
Biomarker sNfL Falls Short for MS Diagnosis, Experts Say
PHOENIX — Despite its growing role in monitoring treatment response and disease activity in multiple sclerosis (MS), serum neurofilament light chain (sNfL) lacks the specificity needed for diagnosis and will not be included in upcoming revisions to the McDonald criteria, experts say. In addition to monitoring treatment response, sNfL has the potential to eventually play a part in predicting disease course, 'but diagnosis? Not so much,' said Tanuja Chitnis, MD, senior neurologist, Brigham M ultiple S clerosis Center, Harvard Medical School, Boston, at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting. This not only applies to sNfL but other fluid biomarkers, including glial fibrillary acidic protein (GFAP), which has enormous promise for tracking and understanding the course of MS but also needs context and has important limitations. 'We do not yet know for sure what the updated McDonald criteria will recommend specifically, but sNfL is not very helpful for diagnosis,' said Mark Freedman, MD, director of the Multiple Sclerosis Research Unit at the University of Ottawa, Ottawa, Ontario, Canada. He, like Chitnis, does not see sNfL as a diagnostic tool either as an isolated value or in the context of other currently available signs of disease. Most, if not all, patients with a diagnosis of MS who are eventually confirmed typically have elevated levels of sNfL, but Freedman, who led the symposium on fluid biomarkers said this information is not helpful. And sNfL, he noted climbs with neurodegeneration, but this is not unique to MS. Many other diseases associated with neuronal damage, including amyotrophic lateral sclerosis, are linked to much higher sNfL levels at diagnosis, underscoring its poor specificity, said Freedman, who has led consensus papers on its use. The most recent was published in 2024 on behalf of the CMSC. An Indicator of Response Chitnis said sNfL may eventually play a role in MS diagnosis when combined with other variables, including fluid biomarkers, but for now, its primary value lies in disease management, where it serves as a sensitive tool for monitoring treatment response. A sensitive indicator of disease activity sNfL provides information beyond MRI, said Chitnis, who tracks levels every 3-6 months after initiating or switching therapy. A lack of decline may signal inadequate disease control. Freedman echoed this view, noting that if levels don't drop within a few months of starting treatment, he begins to question its effectiveness — even before other signs of treatment failure appear. 'If I do not see sNfL fall within a few months of starting therapy, I start questioning the therapy,' he said. The clinical value of sNfL was highlighted in a 2023 CSMC consensus paper, which endorsed its use for tracking recovery after relapse, guiding therapy decisions, and clarifying discrepancies between MRI and clinical findings. Since then, evidence supporting its use has only strengthened, Freedman said. 'The tests are now accessible everywhere,' he said. He also noted that there is growing confidence that sNfL is a substitute for MRI in many specific scenarios, such as when access to MRI is limited by cost or distance to an imaging device. Multiple sNfL assays are available, but they are not interchangeable. They vary in sensitivity, turnaround time, methodology, and cutoff values — so any changes in sNfL levels must be tracked using the same assay throughout. 'We have to be careful about using apps to interpret the results,' Chitnis cautioned, noting that such tools are now commercially available. She added that interpretation also depends on the reference population and can be influenced by factors like body mass index, renal function, and age. 'A Novel Window Into the Brain' The value of sNfL in monitoring treatment response — and in tasks such as assessing disease activity in patients with MS who have discontinued DMT — may be just the beginning for this biomarker, which is under active investigation for a range of additional uses, said Chitnis. She noted that the clinical utility of fluid biomarkers like sNfL is likely to expand significantly as researchers learn how to interpret them in combination. In several studies, pairing sNfL with GFAP has offered new insights into progressive MS, particularly when the two markers trend in opposite directions. Despite an imperfect correlation, patients with high GFAP but low sNfL, relative to the other way around, 'probably represent our nonactive secondary progressive MS disease cohort,' Chitnis said. 'This is getting at our understanding of who might be more progressive in regard to the loss of the glial structure in the brain,' she added. Meanwhile, other potential biomarkers associated with increased clinical and radiological MS activity are showing promise. In a recent study led by Chitnis, a panel of 20 such proteins correlated more precisely with gadolinium lesion activity, clinical relapse, and annualized relapse rate than sNfL alone. Ultimately, fluid biomarkers like sNfL are providing 'a novel window into the brain' relevant not just to monitoring disease but potentially revealing the sequence of underlying pathophysiology of MS, said Chitnis. These appear to differentiate relatively benign disease from events leading to the irreversible damage of late stages progression.
Washington Post
40 minutes ago
- Washington Post
As Trump meets U.S. allies, America's friends see a new world order
When President Donald Trump first barreled into office in 2017, he was the disrupter among world leaders, many of whom sought to wait out what they hoped would be a four-year blip in U.S. history. Now, as he prepares for a weeks-long blitz of encounters with Washington's historic allies that starts Thursday, Trump has taken on a new role in his second term: the definer of a more enduring era to which other nations must adapt.
